Angiopoietin-like protein 2 sensitively responds to weight reduction induced by lifestyle intervention on overweight Japanese men

Nutrition and Diabetes

Volumn 1, Issue 1, 2011, Pages

  Muramoto, A ^a,b   Tsushita, K ^a   Kato, A ^a   Ozaki, N ^b   Tabata, M ^c   Endo, M ^c   Oike, Y ^c   Oiso, Y ^b  

^a Aichi Health Promotion Foundation   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

adiponectin; angiopoietin like protein 2; body weight reduction; lifestyle intervention; metabolic syndrome

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ANGIOPOIETIN 2; ANGIOPOIETIN LIKE PROTEIN 2; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL METABOLISM; CONTROLLED STUDY; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; JAPANESE; LIFESTYLE MODIFICATION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; SMOKING; WEIGHT REDUCTION;

EID: 84884213080     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2011.16     Document Type: Article

References (32)

1. Lee IM, Manson JE, Hennekens CH, Paffenbarger Jr RS. Body weight and mortality. A 27-year follow-up of middle-aged men. JAMA 1993; 270: 2823-2828.
2. Reaven GM. Syndrome X: 6 years later. J Intern Med Suppl 1994; 736: 13-22.
3. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998; 338: 1-7.
4. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
5. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-79.
6. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289: 1799-1804.
7. Bobbert T, Rochlitz H, Wegewitz U et al. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 2005; 54: 2712-2719.
8. Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE et al. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008; 57: 980-986.
9. Madsen EL, Rissanen A, Bruun JM, Skogstrand K, Tonstad S, Hougaard DM et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008; 158: 179-187.
10. Engström G, Hedblad B, Stavenow L, Lind P, Janzon L, Lindgärde F. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes 2003; 52: 2097-2101.
11. Festa A, D'Agostino Jr R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
12. Festa A, D'Agostino Jr R, Tracy RP, Haffner SM. Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-1137.
13. Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-242.
14. Retterstol L, Eikvar L, Bohn M, Bakken A, Erikssen J, Berg K. C-reactive protein predicts death in patients with previous premature myocardial infarction-a 10 year follow-up study. Atherosclerosis 2002; 160: 433-440.
15. Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease-baseline findings of the PAIS project. Atherosclerosis 2001; 156: 451-456.
16. Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003; 23: 1042-1047.
17. Ryan AS, Nicklas BJ. Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. Diabetes Care 2004; 27: 1699-1705.
18. Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 2001; 21: 968-970.
19. Yatsuya H, Jeffery RW, Langer SL, Mitchell N, Flood AP,Welsh EM et al. Changes in C-reactive protein during weight loss and the association with changes in anthropometric variables in men and women: LIFE Study. Int J Obes (Lond) 2010; 35: 684-691.
20. Tabata M, Kadomatsu T, Fukuhara S, Miyata K, Ito Y, Endo M et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab 2009; 10: 178-188.
21. Oike Y, Tabata M. Angiopoietin-like proteins-potential therapeutic targets for metabolic syndrome and cardiovascular disease. Circ J 2009; 73: 2192-2197.
22. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97.
23. The Examination Committee of Criteria for 'Obesity Disease' in Japan, Japan Society for the Study of Obesity. New criteria for 'obesity disease'. Japan Circ J 2002; 66: 987-992.
24. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int 2010; 1: 2-20.
25. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20: 1087-1092.
26. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
27. Okada T, Tsukano H, Endo M, Tabata M, Miyata K, Kadomatsu T et al. Synoviocyte-derived Angiopoietin-like protein 2 contributes to synovial chronic inflammation in rheumatoid arthritis. Am J Pathol 2010; 176: 2309-2319.
28. Knowler WC, Barrett-Connor E, Fowler SE et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
29. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
30. Eriksson KF, Lindgärde F. Prevention of type 2 (non- insulindependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia 1991; 34: 891-898.
31. Bolanowski M, Nilsson RE. Assessment of human body composition using dual-energy X-ray absorptiometry and bioelectrical impedance analysis. Med Sci Monit 2001; 5: 1029-1033.
32. Pateyjohns IR, Brinkworth GD, Buckley JD, Noakes M, Clifton PM. Comparison of three bioelectrical impedance methods with DXA in overweight and obese men. Obesity 2006; 14: 2064-2070.